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Abstract 31 
Hydrochlorothiazide (HCT) is a diuretic BCS class IV drug with poor aqueous solubility and 32 
low permeability leading to poor oral absorption. The present work explores the 33 
cocrystallization technique to enhance the aqueous solubility of HCT. Three new cocrystals 34 
of HCT with water soluble coformers phenazine (PHEN), 4-dimethylaminopyridine (DMAP) 35 
and picolinamide (PICA) were prepared successfully by solution crystallization method and 36 
characterized by single crystal X-ray diffraction (SCXRD), powder X-ray diffraction 37 
(PXRD), fourier transform –infraredspectroscopy (FT-IR), differential scanning calorimetry 38 
(DSC) and thermogravimetric analysis (TGA). Structural characterization revealed that the 39 
cocrystals with PHEN, DMAP and PICA exists in P21/n, P21/c and P21/n space groups, 40 
respectively. The improved solubility of HCT-DMAP (4 fold) and HCT-PHEN (1.4 fold) 41 
cocrystals whereas decreased solubility of HCT-PICA (0.5 fold) as compared to the free drug 42 
were determined after four hours in phosphate buffer, pH 7.4, at 25 °C by using shaking flask 43 
method. HCT-DMAP showed a significant increase in solubility than all previously reported 44 
cocrystals of HCT suggest the role of a coformer. The study demonstrates that the selection 45 
of coformer could have pronounced impact on the physicochemical properties of HCT and 46 
cocrystallization can be a promising approach to improve aqueous solubility of drugs. 47 
 48 
Keywords: Crystal engineering, cocrystal, solubility, thermal analysis, structural analysis.  49 
 50 
 51 
 52 
 53 
 54 
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1. Introduction 56 
The properties of an active pharmaceutical ingredient (API) are broadly determined by 57 
the molecular arrangement in three-dimensional crystal lattice.1 In recent times, many 58 
effective APIs are appearing eventually less in the market place due to poor 59 
biopharmaceutical properties.2 Poor aqueous solubility is one of the crucial problems,3 60 
which affects the dissolution and bioavailability. Therefore, designing a new solid 61 
form with desired physicochemical properties is essential for its progress in the 62 
advanced stage of research and development. Exploitation of non-covalent interactions 63 
of the molecules in the crystal lattice, thereby altering the molecular arrangement may 64 
aid in the development of crystal with desirable physicochemical properties.4 The 65 
various solid forms such as amorphous solids,5 polymorphs,6 salts,7 hydrates8 and 66 
solvates9 have been utilized in tailoring specific physicochemical properties to 67 
overcome the difficulties associated with poor aqueous solubility. The most common 68 
approaches that are used for improving the delivery of poorly soluble drugs includes 69 
salt formation,10 micronisation,11 solid-lipid nanoparticles carrier,12 solid dispersion,13 70 
solubilization of drugs in co-solvents,14 complexation with cyclodextrins,15etc. 71 
Cocrystallization of API with water soluble coformers is an emerging strategy to 72 
achieve the spring and parachute nature of aqueous solubility. It involves the 73 
formation of a homogenous crystalline material of two or more molecules with defined 74 
stoichiometry in a single crystal lattice.16 Non-covalent interactions such as hydrogen 75 
bonding, halogen bonding, π‒π stacking, and van der Waals forces are the most 76 
common type of interactions utilized for engineering of cocrystals.17 77 
Biopharmaceutical properties such as solubility, dissolution, bioavailability, moisture 78 
uptake, chemical stability, mechanical properties have been altered by 79 
cocrystallization.18 Amongst these, solubility and dissolution are the most frequently 80 
studied properties. 81 
Hydrochlorothiazide (HCT, 6-chloro-3,4-dihydro-2H-1,2,4-benzothiodiazine-7-82 
sulfonamide) (Scheme 1) is a diuretic antihypertensive drug of the thiazide family, 83 
widely prescribed for the management of edema and hypertension. However, this API 84 
as per biopharmaceutical classification system (BCS) class IV drug, has poor water 85 
solubility (0.7 g/L) and low permeability (Caco-2 permeability: -6.06) which is a 86 
major barrier in making it bioavailable (65 %) in the body.19 87 
 88 
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 99 
Scheme 1. Chemical structures of hydrochlorothiazide (HCT) and the coformers used 100 
in this study. 101 
 102 
Several researchers have attempted to improve the solubility of HCT by complexation 103 
with cyclodextrins,20 soliddispersions,21 liquid−solid compacts,22 lecithin/chitosan 104 
nanoparticles,23 pluronic® nanoaggregates,24 etc. It reveals that these formulations 105 
could favorably impact an aqueous solubility of HCT. Recently, HCT has also been 106 
investigated for its cocrystallization tendencies where there is a potential for solubility 107 
enhancement at the molecular level. HCT cocrystals involving some coformers were 108 
reported and they exhibited improved aqueous solubility and dissolution than the drug 109 
itself.19,25 110 
Hydrochlorothiazide moiety, the principal functional unit i.e. two sulfonamide and one 111 
aromatic amine group is expected to form S=O···H and N‒H···O hetero-synthons. On 112 
this basis several coformers including aromatic acids and amides were attempted for 113 
cocrystallization with HCT (see Table S1, Electronic Supplementary Information, ESI 114 
for complete list of coformers tested). However, the cocrystals were identified with 115 
only three coformers, phenazine (PHEN), 4-dimethylaminopyridine (DMAP) and 116 
picolinamide (PICA) and are reported herein. From the literature it has been found that 117 
the coformers phenazine (PHEN),26 picolinamide (PICA)28 could form cocrystals or a 118 
coformer, 4-dimethylaminopyridine (DMAP),29 forms salt with APIs and have altered 119 
the physicochemical properties of the API. Thus in this study,we undertaken these 120 
coformers and investigated the solubility of all three HCT cocrystals. 121 
 122 
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123 
2. Experimental section 124 
2.1 Materials 125 
Hydrochlorothiazide and all cocrystal formers (phenazine, 4-dimethylaminopyridine and 126 
picolinamide) were purchased from Sigma-Aldrich chemicals, Bangalore, India. All the 127 
solvents were used (for crystallization) as received without any further purification. 128 
 129 
2.2 Methodology 130 
2.2.1 Cocrystals preparation method 131 
HCT and cocrystal former in a definite stoichiometric ratio were subjected to grinding using 132 
an agate mortar and pestle for about 6 to 8 min with the addition of few drops of methanol. 133 
The Liquid Assisted Grinding (LAG) was used because it is expected to increase 134 
cocrystallization kinetics and for polymorph control.30 After grinding, the mixture was 135 
dissolved in ethanol (or methanol) and the suspension was heated until a clear solution was 136 
obtained. Then the solution was filtered to remove any undissolved particles into a fresh 137 
conical flask and the filtrate was left to evaporate slowly at ambient conditions. The single 138 
crystals suitable for X-ray diffraction studies were obtained in 4 to 6 days.  139 
 140 
2.2.2 Single crystal X-ray diffraction (SXRD) 141 
X-ray diffraction data for all the cocrystals of HCT were recorded on a SuperNova, Eos 142 
diffractometer using monochromatic Mo-Kα radiation (λ = 0.71073 Å). The data collection 143 
was carried out at 246 K for HCT-PHEN, 291 K for HCT-DMAP, and 296 K for HCT-PICA 144 
cocrystals respectively. The structure was solved using Olex2,31 with Superflip32 structure 145 
solution program using Charge Flipping solution method and refined with the ShelXL33 146 
refinement package using Least Squares minimization.  147 
 148 
2.2.3 Powder X-ray diffraction (PXRD) 149 
The PXRD patterns were collected on a RigakuSmartLab with a Cu-Kα radiation (1.540 Å). 150 
The tube voltage and amperage were set at 20 kV and 35 mA, respectively. Each sample was 151 
scanned between 5 and 50° 2θ with a step size of 0.02°. Before performing the experiments, 152 
the instrument was calibrated using a silicon standard. 153 
 154 
2.2.4 Fourier transform-infrared spectroscopy (FT-IR) 155 
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Transmission infrared spectra of all the cocrystals and coformers including HCT were 156 
obtained using a Fourier-transform infrared spectrometer (PerkinElmer502). Before 157 
measuring the spectra for samples, background scan was performed with pure KBr pellet. 158 
Later the samples were pelleted with the help of 2 mg in 15 mg of KBr and 8 scans were 159 
collected at 4 cm-1 resolutions for each sample. The spectra were measured over the range of 160 
4000 - 400 cm-1. 161 
 162 
Differential scanning calorimetry (DSC) 163 
DSC was conducted on a Mettler-Toledo DSI1 STARe instrument. Accurately weighed 164 
samples (4–5 mg) were placed in hermetically sealed 40 µL aluminium crucibles and scanned 165 
from 50 to 300 °C at a heating rate of 10 °C/min under a dry nitrogen atmosphere (flow rate 166 
60 ml/min). The data was managed by STARe software. 167 
 168 
2.2.5 Thermogravimetric analysis (TGA) 169 
TGA was carried out using a Perkin Elmer, Diamond TG/DTA analyzer, operated under 170 
nitrogen atmosphere with a heating rate of 10 °C/min and in the range of 30-300 °C. 171 
 172 
2.2.6 Solubility studies 173 
The solubility of HCT, HCT-PHEN, HCT-DMAP and HCT-PICA were measured in 174 
phosphate buffer, pH 7.4, at 25 °C by using shaking flask method.19 An excess amount of the 175 
drug and cocrystals were added to 20 mL of buffer. The resulting slurry was shaken in a 176 
water bath shaker, maintained at 25 °C for 48 h. Aliquots (0.5 mL) of the slurry were 177 
withdrawn at different time intervals for a period of 48 h to confirm that the solution has 178 
achieved equilibrium. The samples were assayed after suitable dilution for drug content by 179 
HPLC at 227 nm. The amount of drug dissolved in each time interval was calculated using 180 
the standard curve (linearity range: 2-32 µg/mL) which was prepared in phosphate buffer (pH 181 
7.4). The experiment was performed in triplicate and values were expressed as mean ± 182 
standard deviation. 183 
 184 
2.2.7 High performance liquid chromatography (HPLC) 185 
Solution concentration of HCT and its cocrystals were analyzed by HPLC (Knaur) equipped 186 
with a UV/vis detector. A C18 Nova-Pak column 5 µm, 4.6 × 250 mm (Waters, USA) at 187 
ambient temperature with a flow rate of 1 mL/min was used to separate HCT, PHEN, DMAP 188 
and PICA. An isocratic method with acetonitrile and phosphate buffer (pH=2.8) mixed in a 189 
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ratio of 40:60 (v/v), respectively, was optimized for quantitative determination of 190 
hydrochlorothiazide (retention time 3.7 min) at an optimum wavelength of 227 nm. Sample 191 
injection volume was 20µL. Eurochrom software was used to collect and process the data. 192 
3. Results and discussion 193 
Three new cocrystals of HCT with heteroaromatic coformers were synthesized by the 194 
slow evaporative crystallization method (see also experimental section). Crystal 195 
structure analysis was performed to rationalize the hydrogen bonding preferences of 196 
acceptors and donors in presence of other competing functional groups. 197 
Crystallographic data is listed in the Table S2, ESI.  198 
From the available literature on HCT cocrystals, it was found that HCT prefer to bind 199 
with a hetero atom in the coformer. Hence, strategically we chose only heteroaromatic 200 
compounds as coformers for this study. Most common synthons found in the reported 201 
HCT cocrystals are N−H···O and N−H···N by the primary and secondary sulfonamide 202 
groups of HCT with coformers. However, it was observed (in reported and present 203 
cocrystals as well) that the typical synthons, sulfonamide dimer and sulfonamide 204 
catemer that are present in polymorphs of HCT, were disrupted by the coformers to 205 
form a stable cocrystal. A common synthon in all three new cocrystals has been found 206 
as N−H···N between the primary sulfonamide N-H and pyridine N. Amongst the three 207 
studied compounds, only PHEN appeared as a cocrystal hydrate of HCT, which is 208 
similar to the isonicotinamide, which also exists as a cocrystal hydrate with HCT.34 209 
The detailed crystal structure analyses for all the cocrystals are discussed below and 210 
experimental details are provided in the ESI. 211 
 212 
3.1 Hydrochlorothiazide:Phenazine:H2O (1:1:1), (HCT-PHEN.H2O) 213 
The crystal structure of HCT-PHEN.H2O revealed that it is a monohydrate of the 1:1 214 
cocrystal of HCT and PHEN. The cocrystal crystallized in monoclinicP21/n space 215 
group with one molecules of each HCT, PHEN and H2O in the asymmetric unit (Fig. 216 
S1, ESI). In the crystal packing, two molecules of each HCT and H2O formed a 217 
tetrameric motif as shown in Fig. 1. The alternative tetrameric motifs were connected 218 
by PHEN molecules via strong N−H···N (d/Å, θ/°; 0.77 Å, 171°) and moderately 219 
strong O−H···N (0.92 Å, 146°) interactions to form 1D sheets along b-axis. The 220 
interlinked PHEN molecules in the 1D tape are stacked by π - π interactions 221 
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perpendicular to HCT molecular plane. The overall crystal packing from the top view 222 
of a-axis is shown in Fig. 1. 223 
 224 
Fig. 1. HCT-PHEN.H2O crystal packing view along a-axis, where the water molecule 225 
incorporated in the crystal structure is represented with a space fill model. The inset 226 
highlights the tetrameric motif in the crystal packing. 227 
 228 
3.2 Hydrochlorothiazide:4-Dimethylaminopyridine (1:2), (HCT-DMAP) 229 
The cocrystal, HCT-DMAP crystallizes in the monoclinic P21/c space group with one 230 
molecule of HCT and two molecules of DMAP in the asymmetric unit (Fig. S2, ESI). 231 
The HCT molecules form 2D sheets via N−H···O (0.86 Å, 166°) interactions along c-232 
axis and C−H···O (2.714 Å, 121°) interactions along a-axis (Fig. 2a). In the third 233 
dimension the DMAP molecules are sandwiched between the HCT 2D-sheets (Fig. 234 
2b).  235 
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 236 
Fig. 2. Crystal packing of HCT-DMAP where (a) 2d sheet in ac plane and (b) crystal 237 
packing, when viewed down a-axis.  238 
 239 
3.3 Hydrochlorothiazide:Picolinamide (1:1), (HCT-PICA) 240 
The PICA is a positional isomer of nicotinamide (NIC) and isonicotinamide (INIC). 241 
NIC and INIC were reported as a cocrystal and cocrystal monohydrate of HCT, 242 
respectively.25a. Here the cocrystal HCT with PICA crystallizes in the monoclinic 243 
P21/n space group with one molecule of each HCT and PICA in the asymmetric unit 244 
(Fig. S3, ESI). Though the three coformers NIC, INIC, and PICA are isomers, they 245 
form cocrystals with HCT in three different crystal systems as orthorhombic, triclinic 246 
and monoclinic respectively. This means that the position of heteroatom of the 247 
coformer is deciding the crystal system by forming different types of intermolecular 248 
interactions with HCT.  249 
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In the crystal structure of HCT–NIC co-crystal, NIC molecules form 1D chains 250 
through amide·· ·pyridine (N−H···N) synthons and HCT molecules are sandwiched 251 
between these alternate 1D chains. But, the INIC molecules in the crystal structure of 252 
HCT−INIC−H2O form amide-amide supramolecular homosynthons and are linked to 253 
HCT molecules by water molecules. Here, the water molecules act as both H-bond 254 
donor (to pyridyl moieties of INIC) and acceptor (to sulfonamide groups of HCT). The 255 
crystal packing in the present case HCT-PICA is completely different compared to 256 
above two. Here, a two molecules of each HCT and PICA form a tetrameric motif 257 
(Fig. 3a) via N−H···O (0.86 Å, 160°; 0.96 Å, 150°) interactions. In the overall crystal 258 
packing the tetramers were propagated along the b and c-axes directions via N−H···N 259 
and N−H···O interactions, respectively (Fig. 3b). 260 
  261 
Fig. 3. Crystal packing diagram of HCT-PICA. (a) Tetrameric motif in the crystal packing 262 
formed by two molecules of HCT and two molecules of PICA. (b) Crystal packing, when 263 
viewed down a-axis.  264 
3.4 Powder X-ray diffraction (PXRD) 265 
PXRD is a powerful tool for preliminary characterization of new solid forms as well as 266 
cocrystals.35 In each case freshly prepared powder samples were used for the data 267 
collection. The PXRD patterns for all the cocrystals were plotted in comparison with 268 
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respective individual coformers and simulated PXRD pattern (Fig. S4, ESI). The 269 
absence of characteristic peaks of starting compounds and the close superimposition of 270 
the experimental and simulated patterns confirm the cocrystal formation. 271 
 272 
3.5 FT-IR analysis 273 
The cocrystals were further characterized by FT-IR spectroscopy, which is a cogent 274 
tool to make sure the cocrystal formation. The comparison of the stretching frequency 275 
shifts as shown in Fig. S6, ESI corroborated the formation of hydrogen bonds between 276 
the functional groups in cocrystals. At first instance, the SO2 asymmetric region 277 
(1320–1380 cm-1) was found to be very broad in the FT-IR spectra of HCT than when 278 
compared to the same region in the spectra of cocrystals. Furthermore, The NH and 279 
NH2 stretching frequencies in free HCT observed at 3267 and 3361 cm-1 respectively. 280 
But, in the cocrystals the NH frequency merged with NH2 and appeared as a broad 281 
peak compared to free HCT. 282 
 283 
3.6 Thermal analysis 284 
Thermal behavior of all the cocrystals was investigated by differential scanning 285 
calorimetry (DSC) and thermogravimetric analysis (TGA). DSC results have revealed 286 
that the melting point of all cocrystals except for the monohydrate cocrystal (HCT-287 
PHEN) were distinct from HCT (267-269 °C) and individual coformers. In the case of 288 
HCT-PHEN, loss of crystalline water leads to dissociation of cocrystal. This confirms 289 
the formation of new crystalline phase. The melting point of HCT-DMAP and HCT-290 
PICA cocrystals were observed as 138 °C, and 159 °C, respectively (Fig. S5, ESI).  291 
In the TGA curve of HCT-PHEN, there was a weight loss of 4.19 % in the temperature 292 
range of 100-145 °C which corresponds to loss of one water molecule. This value is in 293 
accordance with the theoretical mass loss of 3.7 % for desolvation of one mole of 294 
water from the crystal lattice of HCT-PHEN. Next, there was a weight loss of 34.43 % 295 
in the temperature range of 147-197 °C. This can be attributed to the 296 
degradation/sublimation of one mole of phenazine (theoretical weight loss 36.36%). 297 
This event is followed phase transition and melting of hydrochlorothiazide. Similarly, 298 
for all other HCT cocrystals, TGA profiles corroborated well with the DSC results and 299 
their data is presented in the ESI (Fig. S5). 300 
 301 
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3.7 Solubility Studies 302 
HCT is a poorly soluble drug (0.7 g/L)1. Poor aqueous solubility not only limits its 303 
dissolution and absorption but also challenges its pharmaceutical development. 304 
Cocrystallization was employed to modify the solubility of HCT. The solubility profile 305 
of hydrochlorothiazide and its cocrystals are illustrated in Fig. 4. It was observed that 306 
cocrystallization markedly increase the solubility of HCT. It was found that the 307 
solubility of HCT and its cocrystals after four hours follows the rank order: HCT-308 
DMAP (4 fold) > HCT-PHEN (1.4 fold) > HCT > HCT-PICA. The solubility studies 309 
conducted by Desiraju et al. (2015) reported improved solubility of HCT-para-310 
aminobenzoic acid (2.4 times), HCT-resorcinol (1.3 times), HCT-nicotinamide (1.2 311 
times) as compared to HCT.19Interestingly, our results suggest that HCT-DMAP has 312 
exhibited the highest transient solubility among the HCT cocrystals reported thus far. 313 
The parachute nature of the HCT-DMAP cocrystal extended till 48 hours. On the other 314 
hand, HCT-PICA showed poor aqueous solubility as compared to HCT, which is in 315 
accordance with a literature finding of a couple of other HCT cocrystals.19Further, it 316 
reveals a selection of suitable coformer can lead to a potential modulation in the 317 
solubility of HCT in either direction.  318 
 
319 
 320 
Fig. 4.Solubility profile of hydrochlorothiazide and its cocrystals (Avg. value ± SD (n=3)). 321 
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4. Conclusions 322 
In this study, cocrystallization was explored to address the solubility issues of 323 
hydrochlorothiazide. The strategy to exploit the preferable binding nature of HCT with 324 
the hetero atom in the coformer has been demonstrated successfully by obtaining three 325 
new solid forms. The formation of cocrystals was confirmed by thermal, FT-IR, 326 
PXRD, and single crystal X-ray diffraction studies. The melting points of all the three 327 
cocrystals were lower than API but higher than the corresponding coformer. The 328 
solubility of the drug and cocrystal after four hours follows the order HCT-DMAP (4 329 
fold) > HCT-PHEN (1.4 fold) > HCT > HCT-PICA. HCT-DMAP solubility results 330 
suggest that a selection of an appropriate coformer would have a great potential to 331 
increase the solubility of HCT. Thus, cocrystallization approach proved to be a 332 
promising alternative in positively modifying the solubility of hydrochlorothiazide. 333 
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Highlights 
1) Three new cocrystals of HCT with water soluble coformers were successfully prepared 
by solution crystallization method. 
2) Transient Solubility of HCT was increased by 4 fold in case of HCT-DMAP cocrystal. 
3) Selection of coformer is vital, otherwise reduced solubility can be observed as in the case 
of HCT-PICA. 
